Everolimus granted EU orphan drug designation for the treatment of gastro-entero-pancreatic neuroendocrine tumours (EMEA, 11 January 2008)

15 Jan 2008

Orphan designation has been granted by the EC to Novartis Europharm Limited, United Kingdom, for everolimus for the treatment gastro-entero-pancreatic neuroendocrine tumours.